Immune response in COVID-19: What do we currently know?

被引:13
|
作者
Oliveira, Daniela S. [1 ]
Medeiros, Nayara I. [1 ,2 ]
Gomes, Juliana A. S. [1 ]
机构
[1] Univ Fed Minas Gerais, Lab Biol Interacoes Celulares, Dept Morfol, Inst Ciencias Biol, Belo Horizonte, MG, Brazil
[2] Fundacao Oswaldo Cruz FIOCRUZ, Imunol Celular & Mol, Inst Rene Rachou, Belo Horizonte, MG, Brazil
关键词
RESPIRATORY SYNDROME CORONAVIRUS; MERS-COV; MEMORY; SARS; REPLICATION; INFECTION; PATHOGENESIS; PATHOLOGY; CELLS; ANTIBODIES;
D O I
10.1016/j.micpath.2020.104484
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In 2002/2003 there was a pandemic denominate SARS (severe acute respiratory syndrome), caused by the SARS-CoV virus that belongs to the genera Betacoranavirus and the family Coronaviridae, generally responsible for influenza infections. In mid of 2019, a new disease by the coronavirus named by COVID-19 (SARS-CoV-2) emerged, both infections have flu symptoms, however they are infections that variable intensity, being medium to severe. In medium infections individuals have the virus and exhibit symptoms, however hospitalization is not necessary, in severe infections, individuals are hospitalized, have high pathology and in some cases progress to death. The virus is formed by simple positive RNA, enveloped, non-segmented, and presenting the largest genome of viruses constituting 32 Kb, consisting of envelope proteins, membrane, nucleocapsid and spike protein, which is essential in the interaction with the host cells. As for the origin of this virus, research has been intensified to determine this paradox and although the similarity with SARS-CoV, this virus did not has necessarily the same place of origin. As for the immune system, it is currently unknown how this new virus interacts. In this brief review, we demonstrate important considerations about the responses to this infection.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Liver injury in COVID-19: What do we know now?
    Yang, Hua-Yu
    Jin, Bao
    Mao, Yi-Lei
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2020, 19 (05) : 407 - 408
  • [42] Facing the COVID-19 outbreak: What should we know and what could we do?
    Yang, Yi
    Shang, Weilong
    Rao, Xiancai
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (06) : 536 - 537
  • [43] What We Know (and Do not Know) Regarding the Pathogenesis of Pulmonary Thrombosis in COVID-19
    Lippi, Giuseppe
    Favaloro, Emmanuel J.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2023, 49 (01): : 27 - 33
  • [44] Cathinones: What do we currently know?
    Sastre, Caroline
    Mazoyer, Cedric
    Mayer, Charlotte
    Grosjean, Jerome
    Di Fazio, Vincent
    Saussereau, Elodie
    TOXICOLOGIE ANALYTIQUE ET CLINIQUE, 2014, 26 (03) : 148 - 155
  • [45] COVID-19 and Cardiovascular Surgery. Do We Know What We Are Dealing With?
    Almeida, Rui M. S.
    Marin-Cuartas, Mateo
    Garcia-Villarreal, Ovidio A.
    Dayan, Victor
    BRAZILIAN JOURNAL OF CARDIOVASCULAR SURGERY, 2021, 36 (06) : III - IV
  • [46] Awareness of the Egyptian public about COVID-19: what we do and do not know
    Sabry, Nirmeen
    ElHadidi, Seif
    Kamel, Ahmed
    Abbassi, Maggie
    Farid, Samar
    INFORMATICS FOR HEALTH & SOCIAL CARE, 2021, 46 (03): : 244 - 255
  • [47] COVID-19: What we can know
    Wildner, Manfred
    GESUNDHEITSWESEN, 2020, 82 (06) : 493 - 496
  • [48] Psychological Intervention and COVID-19: What We Know So Far and What We Can Do
    Inchausti, Felix
    MacBeth, Angus
    Hasson-Ohayon, Ilanit
    Dimaggio, Giancarlo
    JOURNAL OF CONTEMPORARY PSYCHOTHERAPY, 2020, 50 (04) : 243 - 250
  • [49] Psychological Intervention and COVID-19: What We Know So Far and What We Can Do
    Felix Inchausti
    Angus MacBeth
    Ilanit Hasson-Ohayon
    Giancarlo Dimaggio
    Journal of Contemporary Psychotherapy, 2020, 50 : 243 - 250
  • [50] COVID-19 in Children: What We Know and What We Don’t Know?
    Kana Ram Jat
    Indian Journal of Pediatrics, 2021, 88 : 961 - 961